Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2012 Aug 20;30(24):2995-3001.
doi: 10.1200/JCO.2012.42.1925. Epub 2012 Jul 16.

Patterns of survival among patients with myeloproliferative neoplasms diagnosed in Sweden from 1973 to 2008: a population-based study

Malin Hultcrantz  1 , Sigurdur Yngvi Kristinsson, Therese M-L Andersson, Ola Landgren, Sandra Eloranta, Asa Rangert Derolf, Paul W Dickman, Magnus Björkholm
Affiliations

Patterns of survival among patients with myeloproliferative neoplasms diagnosed in Sweden from 1973 to 2008: a population-based study

Malin Hultcrantz et al. J Clin Oncol. .

Abstract

Purpose: Reported survival in patients with myeloproliferative neoplasms (MPNs) shows great variation. Patients with primary myelofibrosis (PMF) have substantially reduced life expectancy, whereas patients with polycythemia vera (PV) and essential thrombocythemia (ET) have moderately reduced survival in most, but not all, studies. We conducted a large population-based study to establish patterns of survival in more than 9,000 patients with MPNs.

Patients and methods: We identified 9,384 patients with MPNs (from the Swedish Cancer Register) diagnosed from 1973 to 2008 (divided into four calendar periods) with follow-up to 2009. Relative survival ratios (RSRs) and excess mortality rate ratios were computed as measures of survival.

Results: Patient survival was considerably lower in all MPN subtypes compared with expected survival in the general population, reflected in 10-year RSRs of 0.64 (95% CI, 0.62 to 0.67) in patients with PV, 0.68 (95% CI, 0.64 to 0.71) in those with ET, and 0.21 (95% CI, 0.18 to 0.25) in those with PMF. Excess mortality was observed in patients with any MPN subtype during all four calendar periods (P < .001). Survival improved significantly over time (P < .001); however, the improvement was less pronounced after the year 2000 and was confined to patients with PV and ET.

Conclusion: We found patients with any MPN subtype to have significantly reduced life expectancy compared with the general population. The improvement over time is most likely explained by better overall clinical management of patients with MPN. The decreased life expectancy even in the most recent calendar period emphasizes the need for new treatment options for these patients.

PubMed Disclaimer

Figures

Fig 1.
Fig 1.
Cumulative relative survival among patients with myeloproliferative neoplasms (MPNs) in Sweden, stratified by subtype, during the whole study period from 1973 to 2008. ET, essential thrombocythemia; MPN-U, MPN unclassifiable; PMF, primary myelofibrosis; PV, polycythemia vera; RSR, relative survival ratio.
Fig 2.
Fig 2.
Cumulative relative survival among patients with myeloproliferative neoplasms (MPNs) in Sweden, stratified by subtype, diagnosed (A) during the years 1993 to 2008 and (B) during the most recent calendar period of 2001 to 2008. ET, essential thrombocythemia; MPN-U, MPN unclassifiable; PMF, primary myelofibrosis; PV, polycythemia vera; RSR, relative survival ratio.
Fig 3.
Fig 3.
Cumulative relative survival among patients with myeloproliferative neoplasms in Sweden stratified by calendar period of diagnosis. RSR, relative survival ratio.
Fig 4.
Fig 4.
(A) Cumulative relative survival among patients with myeloproliferative neoplasms (MPNs) in Sweden stratified by age at diagnosis and (B) estimates of 5-year cumulative relative survival ratios (RSRs) among patients with MPNs stratified by age and calendar period of diagnosis.
See this image and copyright information in PMC

References

    1. Swerdlow SH, Campo E, Harris NL, et al. Lyon, France: IARC Press; 2008. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues.
    1. Kralovics R, Passamonti F, Buser AS, et al. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med. 2005;352:1779–1790. - PubMed
    1. Levine RL, Wadleigh M, Cools J, et al. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell. 2005;7:387–397. - PubMed
    1. James C, Ugo V, Le Couédic JP, et al. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature. 2005;434:1144–1148. - PubMed
    1. Baxter EJ, Scott LM, Campbell PJ, et al. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet. 2005;365:1054–1061. - PubMed

Publication types